






INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : G01N 33/543		A1	(11) International Publication Number: WO 00/45171
			(43) International Publication Date: 3 August 2000 (03.08.00)
(21) International Application Number: PCT/US00/01749		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 26 January 2000 (26.01.00)			
(30) Priority Data: 60/117,578 27 January 1999 (27.01.99) US			
(71) Applicant (for all designated States except US): BAYER CORPORATION [US/US]; 100 Bayer Corporation, Pittsburgh, PA 15205 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): NI, Wei-Chao [US/US]; 9 Robbins Road, Foxboro, MA 02035 (US). EUSTACE, Daniel, W. [US/US]; 115 West Street, North Attleboro, MA 02760 (US). CHANG, Steve, Chin-Shen [US/US]; 65 Miller Street, Franklin, MA 02038 (US).			
(74) Agents: ROESLER, Judith, A.; Bayer Corporation, 63 North Street, Medfield, MA 02052 (US) et al.		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: IMMUNOASSAYS USING CASEIN COATING OF PARTICLES

(57) Abstract

It has been found that casein and salts of casein are useful as replacements for, or in addition to, BSA as materials for coating solid phases, particularly magnetic particles, used in immunoassays and other binding assays for separation of the desired analyte. By using casein, immunoassays having improved stability and fewer discordant samples have been developed. Casein used at a concentration of 0.05 - 4.0 grams per gram of paramagnetic particle (optimally approximately 0.78-1.2 grams of casein per gram of magnetic particle) has been found to confer this benefit. In addition, a process for coating solid phases has been invented, said process comprising the mixing of casein with magnetic particles at 30-60 °C for 5-180 hours, said process resulting in casein-coated paramagnetic particles which either (1) already have combined therewith active ingredients needed in the binding assay or (2) are capable of reacting with active ingredients needed in the binding assay. Furthermore, a process for using the casein-coated paramagnetic particles has been developed, said particles being directly or indirectly combined with active ingredients used in the immunoassays.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION

IMMUNOASSAYS USING CASEIN COATING OF PARTICLES

5

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. 119(e) to U.S. Provisional Patent Application No. 60/117,578, filed January 27, 1999, entitled
10 STABILIZATION OF PARTICLES AND REDUCTION OF DISCORDANT SAMPLES IN IMMUNOASSAYS USING CASEIN COATING OF PARTICLES.

FIELD OF THE INVENTION

15 This invention relates to coated particles used in binding assays. It also relates to the process for making said particles and the process for using said particles.

20 BACKGROUND OF THE INVENTION

Binding assays, including immunoassays, are commonly used medical diagnostic tools for determining the presence, and the concentration, of various analytes. Immunoassay procedures have been known for
25 many years and include the earlier manual procedures followed by the more recent automated procedures (e.g., those run on the Bayer ACS:180® and ADVIA® Centaur™ Instruments).

30 One of the components used in the immunoassays is a solid phase, frequently a paramagnetic particle (PMP), which is prepared by coating a magnetic particle with a material which allows further reaction of the magnetic

- 2 -

particle with active ingredients used in the immunoassay. In the past, the magnetic particle has been frequently coated with bovine serum albumin (BSA). However, the particles coated with BSA have occasionally
5 been found to be unstable and to yield unreliable assay results. In addition, the use of BSA alone results in high non-specific binding.

BRIEF SUMMARY OF THE INVENTION

10 It has been found that casein and salts of casein are useful as replacements for, or in addition to, BSA as materials for coating solid phases, particularly magnetic particles, used in immunoassays and other binding assays for separation of the desired analyte.
15 By using casein, immunoassays having improved stability and less sample discordance have been developed. Casein used at a concentration of approximately 0.05 - 4.0 grams per gram of paramagnetic particle (optimally approximately 0.78-1.2 grams of casein per gram of
20 magnetic particle) has been found to confer this benefit.

In addition, a process for coating solid phases has been invented, said process comprising the mixing of casein with magnetic particles at 30-60°C. for 5-180
25 hours, said process resulting in casein-coated paramagnetic particles which either (1) already have combined therewith active ingredients needed in the binding assay or (2) are capable of reacting with active ingredients needed in the binding assay.

30 Furthermore, a process for using the casein-coated paramagnetic particles has been developed, said

- 3 -

particles being directly or indirectly combined with active ingredients used in the immunoassays.

BRIEF DESCRIPTION OF THE DRAWINGS

5 Figure 1 shows particle size distribution (in % volume change vs. particle size) of the solid phase in the ferritin assay when 1.2 grams of BSA or casein per gram of PMP were used to coat the solid phase.

10 Figure 2 shows stability at 37°C. (in % dose recovery vs. time in days) for both Testosterone and FT3 for both BSA-coated magnetic particles (present) and casein coated particles (modified).

15 Figure 3 shows Simulated On-Board Stability (in % dose recovery vs. time in days) for FT3, T3 and T4 for both BSA-coated magnetic particles (present) and casein-coated particles (modified).

20 Figure 4 shows Simulated On-Board Stability (in % TU Ratio recovery vs. time in days) for T-uptake for both BSA-coated magnetic particles (present) and casein-coated particles (modified).

 Figure 5 is a correlation study showing % T-Uptake for 100 patient samples, each tested using the casein-coated solid phase (modified) vs. the BSA-coated solid phase (present).

25 Figure 6 shows solid phase stability at 37°C. for the CA 19-9 assay (in % dose recovery vs. time in days) for 3 different analyte levels for both BSA-coated magnetic particles (w/o casein) and casein coated-particles (casein).

30

- 4 -

DETAILED DESCRIPTION OF THE INVENTION

Binding assays have been used for many years as a means for determining the presence of, and the concentration of, analytes when conducting medical diagnostic tests. The term binding assays is intended to cover a wide range of assays, including nucleic acid assays, gene probe assays, immunoassays, and membrane binding. In general, these assays incorporate the reaction of an analyte (or something that can be correlated with analyte concentration) with a solid phase, in order to separate the analyte from a solution, and reaction with a label that will allow detection of the analyte.

Two major types of immunoassays are competitive assays and non-competitive assays. In a competitive assay, the signal which is measured is that emanating from the specific binder that does not bind analyte. There are numerous formats of competitive assays. For example, in some competitive assays, the labeled antibody is incubated with a sample containing analyte and a solid phase-immobilized analyte derivative. The labeled antibody that did not bind analyte binds the solid phase, and the signal emanating from the solid phase-bound labeled antibody is measured. In other types of competitive assays, unlabeled antibody is incubated with a sample containing an analyte and a labeled analyte derivative (or analyte mimic). The labeled analyte derivative binds those antibody binding sites which are unoccupied. By measuring the signal coming from the labeled analyte derivative that bound the antibody, the chemist actually obtains an estimate

- 5 -

of the concentration of antibody sites that did not bind analyte. Thus, in both types of competitive assays, one measures signal associated with the fraction of specific binder sites that did not bind analyte. The signal
5 generated from a competitive assay decreases as the analyte concentration increases. Since small levels of analyte correspond to large signals, small changes in low concentrations of analyte lead to small differences between large numbers, which are hard to measure
10 accurately.

A second type of binding assay is the non-competitive type. In this assay, a labeled specific binder, for example a labeled antibody, is incubated with the sample and binds a portion of the analyte. In
15 one variation of non-competitive assay, a solid-phase immobilized unlabeled specific binder is added, simultaneously or in sequence, to bind another epitope on the analyte, in which case it is called a "sandwich" assay. For example, the immobilized molecule might be
20 an antibody against a second epitope on the analyte, and the analyte might form a ternary complex with the labeled antibody and an immobilized unlabeled antibody. The solid phase is then washed and the signal measured is the signal that comes from the ternary complex
25 containing the analyte. In this case the signal increases with increasing analyte concentration.

All of the assays discussed above are based on the use of a solid phase and a label that becomes attached (or bound or associated) with the solid phase. Many
30 types of labels have been used in binding assays, for example radiochemical, luminescent, fluorescent, chemiluminescent, enzymatic, liposomal and various metal

- 6 -

and non-metal particles. Preferably the label is a chemiluminescent label, such as an acridinium ester. The label can be attached directly to the binder by a covalent bond, or it can be indirectly attached using a binding pair, such as biotin/avidin, DNP/anti-DNP or any other binding pair.

The solid phase is generally separated from the reaction mixture at some stage of the process, and the amount of label attached to said solid phase is determined. The solid phase is generally made of particles made of controlled-pore glass, polymer particles, latex, colloidal metal or metal oxide particles, immiscible liquid phase, extended surface, porous paper, porous gel, liposome, lipos cellulose beads, emulsion, a system of very small particles that do not settle readily by standing or centrifugation, paramagnetic particles, cellulose beads, cross-linked dextran or any other particle. These can include particles that can vary in size from 10 nm to several microns in diameter, larger beads of any size, flat surfaces, test tube walls, dipstick surfaces, fibers, membranes, rods, discs, any extended or particulate surface capable of carrying an immobilized binder. A preferred solid phase is a magnetic particle or an extended surface.

The use of magnetic particles in assays involving separation steps has been known for some time. (See U.S. Patent No. 4,554,088.) The magnetic particles frequently are reacted with intermediates (e.g., silanes and glutaraldehyde) in order to attach the biologically active component. Bovine serum albumin frequently has been used as one of these binding components.

- 7 -

In producing the magnetic particles, it was found that the instability was due to there being a thin coating of BSA on the PMP (i.e., low coating ratio of BSA to PMP). In addition, the BSA coated particles
5 caused interference and sample discordance (i.e., incorrect assay results) in some assays.

It was found that casein, an inert protein, when used as a replacement for BSA or in addition to BSA, helped to eliminate the problems. When casein was used
10 in the range of 0.05-4.0 grams of casein per gram of PMP, preferably in the range of 0.15-3.2 grams of casein per gram of PMP, and most preferably 0.78-1.2 grams of casein per gram of PMP, the problems were much reduced. The mixing of casein with the PMP took place at
15 approximately 30-60°C. for 5-180 hours, preferably at approximately 37-50°C. for 14-144 hours. (A typical process for making casein-coated particles (used in the ferritin assay) is shown in Example 5. Variations of this process may be used when making solid phases for
20 other assays.)

The particle stability was investigated by evaluating particle size distribution before and after rocking on an ADVIA® Centaur™ instrument. The rocking takes place when the reagents are mixed when the assay
25 is run on the instrument. The casein-coated particles exhibited less aggregation or deaggregation due to particle interactions. Thus the casein is believed to have served as a cushion layer, which protected the particles from forming aggregates. See Figure 1, which
30 shows particle size distribution of the solid phase used in the Ferritin Assay, when rocked vs. static, said

- 8 -

reagent being coated with 1.2 grams BSA/gram of PMP (Fig. 1a) or 1.2 grams casein/gram PMP (Fig. 1b).

Thermal stability was investigated with total human chorionic gonadotropin (ThCG), testosterone, CA 19-9 and free T3 and found to be significantly improved for the particles coated with casein. (See Figure 2 and 6, Tables 1 and 5 and Example 1, below.) On-board stability and stored calibration stability (conducted as described below) were also found to be improved for T4, T3, free T3, and T-uptake. (See Example 2 (below), Table 2 and Figures 3-4.)

Stored calibration stability was investigated as follows. At day 0, a calibration point from the reagent formulations stored at 2-8°C. on an ADVIA® Centaur™ analyzer was assayed. A time-course study using the stored reagents was followed subsequently for 28 days. On a specific day, assays with both BSA-coated particles and casein-coated particles were performed. Each data point was compared to the day 0 stored calibration point for the corresponding reagent. The percent of dose recoveries of controls and patient sample pools with respect to day 0 was determined.

To conduct on-board stability tests, samples were stored in the refrigerated (2-8°C.) chamber of the ADVIA® Centaur™, which rocked the samples continuously. A sample was tested before the experiment began (day 0 value). Further samples were removed periodically (up to day 28) for analysis. The results were plotted vs. the data from day 0 to determine the effect of on-board storage on product performance.

- 9 -

Casein or its salts, such as sodium caseinate and potassium caseinate, have been found to be useful coating agents. The choice of form of casein depends, in part, on the medium in which the synthesis is conducted. For example, casein itself is hydrophobic and has relatively poor solubility in aqueous solutions. The salt sodium caseinate, on the other hand, has even better solubility in aqueous solutions, which leads, therefore, to higher concentrations of the caseinate in aqueous solutions and, subsequently, to thicker films of casein being deposited on the solid phase.

The use of BSA, the material generally used for coating solid phase particles, was responsible for interferences and non-specific binding. It is suspected that, since BSA had multiple binding sites for ligands, it allowed interferences by endogenous substances (i.e., those produced in humans), such as L-thyroxine, progesterone, testosterone, estradiol and cortisol. In addition, negatively charged drugs (such as ibuprofen and salicylate, etc.), neutral drugs (such as warfarin and iopanoate, etc.), positively charged drugs (such as quinidine, procaine and lidocaine, etc.), and inorganic ions (such as Cu^+ , Mn^{+2} , Ni^{+2} , Co^{+2} , Ca^{+2} , and Mg^{+2}) have been found to cause interference.

The multiple binding sites on BSA can possibly result in sample discordance if the patient is being medicated with certain drugs. It is known that many drugs strongly bind to albumins. (See Ulrich Kragh-Hansen, 33 Pharmacological Reviews (1981) 17-53, Molecular Aspects of Ligand Binding to Serum Albumin.) Upon binding the drug molecules to BSA, there can be a triggering of side reactions on particles in addition to

- 10 -

the expected antigen-antibody binding reaction. This can complicate the assay system and result in a false signal for sample discordance. Replacing BSA with inert casein on the particle surface can eliminate this problem. Even if the BSA is not totally eliminated, but the casein is the major coating agent (comprising at least 75% of the casein/BSA mixed coating), an improvement is observed.

Changing to casein as the coating material eliminated interferences from thyroid hormone, steroid hormone binding and other non-specific binding. For example, in the T4 assay, the change from BSA to casein resulted in the least detectable dose being reduced from 0.24 μ /dl to 0.18 μ /dl. Moreover, the precision at the low end of the assay (1.12 μ /dl) was significantly improved, and the coefficient of variation was improved from 26.5% to 9.3%.

Casein has been used previously in diagnostic assays, but not for coating particles and not for improving stability. In Snyder (US Patent No. 4,828,980), casein was used to coat membrane structures in order to prevent the non-specific binding of proteins to the membrane surface. In Warren (US Patent No. 4,812,414), particles which contain tracers (labels) were reacted with casein to reduce background signals from positively and negatively charged materials (see col. 2, lines 5-13, 57-60 therein). (I.e., it showed some benefit only when preventing charge-charge interaction.) The casein was not demonstrated to show any benefit with non-charged receptor molecules. In addition, Warren used the casein on the label phase (see claim 1 therein), and the casein was added

- 11 -

simultaneously with the addition of antibody (see col. 13, lines 24-29 of '414). Freitag (US Pat. No. 5,132,208) discloses test strips used in some immunoassays in which the solid component (a polyester fabric) is coated with a protein which is insoluble in the sample liquid under the test conditions. Casein was found to be useful in those assays, since it was found to be almost completely insoluble and allows the active reagent to be deposited on the casein-coated fabric.

It is believed that the use of casein will improve stability in all types of immunoassays, including those for thyroid-related assays (e.g., T-uptake, thyroxine (T4), 3, 3', 5- triiodothyronine (T3), free 3, 3', 5- triiodothyronine (free-T3)), anemia assays (e.g., ferritin), hormone assays (e.g., total human chorionic gonadotropin, testosterone), and cancer marker assays (e.g., CA19-9).

The following examples are intended to exemplify, but not limit, the invention.

EXAMPLE 1

Thermal stability

Thermal stability of casein-coated particles at 37 °C. were conducted by placing several bottles of reagent into an oven and removing one bottle at each test point for analysis. The use of the casein-coated particles showed a significant improvement, as shown by comparing the concentration of analyte determined as a function of time vs. the analyte concentration found at the beginning of the experiment. The results shown in Figure 2 show that there is significant improvement with the casein-coated particle (referred to as "modified").

- 12 -

Stability in assays for testosterone and FT3 are shown in Fig. 2, while the data for stability in the ThCG assay is shown in Table I. Thermal stability for CA 19-9 is shown in Figure 6 and Table 5.

5

EXAMPLE 2

On-Board Stability (Simulating Mixing in an Automated Instrument)

On-board stability tests were conducted to determine the impact of casein coating. The on-board stability tests simulated the continuous mixing conducted by the ADVIA® Centaur™ instrument when the assay was conducted. See data in Figures 3 and 4 and in Table 2 for assay data from free T3, T3, T4 and T uptake data. The other assay performance criteria for T-uptake remained equivalent, as shown in Figure 5 and Table 3.

15

EXAMPLE 3

T4 Performance test

20

A performance test was conducted using reagents for the T4 assay, with one version containing BSA coated onto PMP (see "Present" in Table 4) vs. PMP coated with casein ("Modified" in Table 4). See the improvement noted in Table 4 for Least Detectable Dose and Precision. In the other attributes, no change was noted between the BSA- and casein-coated solid phases, thus indicating that the casein-containing assay remained reliable. (Note that the "Modified" solid phase contained 0.1 g BSA and 1.0 g casein / g PMP.)

25

30

- 13 -

EXAMPLE 4

CA 19-9 Stability

5 Stability in the assay for CA19-9, a cancer marker,
has been significantly improved by the addition of
casein to the solid phase used in that assay. See
Figure 6 and Table 5, which show the significantly
improved stability at 3 analyte levels (22.0, 88.9, and
10 173 U/mL).

EXAMPLE 5

Typical process for making casein-coated particles

- 15 1. PMP is activated by addition of 3.125%
glutaraldehyde (in 0.01M sodium acetate, pH 5.5) which
mixes for 3 hours at room temperature.
- 20 2. Antibody is coupled to the glutaraldehyde
activated PMP, by adding 140 mg antibody/g PMP and
reacting for 16.5 hours at room temperature while
mixing.
- 25 3. The unreacted aldehyde is quenched by reaction
with ethanolamine. The PMP's are magnetically separated
by application of a magnetic force to the container.
The particles are washed with 0.1 M sodium phosphate
buffer (pH 8.0) and then resuspended in 0.1 M sodium
phosphate buffer (pH 8.0). To the suspended particles
is added ethanolamine (1.1M in the final reaction
mixture), and the mixture is stirred for 1 hour at room
temperature.
- 30 4. The Schiff base is reduced by addition of
borane-pyridine. The particles are separated via
application of a magnetic field and are washed with 0.1

- 14 -

M sodium phosphate buffer (pH 8.0) and then resuspended in 0.1 M sodium phosphate buffer (pH 8.0). Borane-pyridine (borane-pyridine mixed with dimethyl sulfoxide at 1 : 4 vol/vol ratio), 50-100 mM in final reaction mixture, is added and allowed to react for 1 hour at room temperature.

5 5. The particles are separated via application of a magnetic force and washed with 1 M NaCl solution. The particles are washed with 0.01 sodium phosphate buffer (pH 8.0). The particles are washed with Heat Stress Buffer and then resuspended in Heat Stress Buffer, and the mixture is incubated at 50° C for 16.5 hours. (Heat Stress Buffer consists of 0.220 g/L sodium phosphate (monobasic), 4.03 g/L sodium phosphate (dibasic), 8.75 g/L sodium chloride, 1 g/L sulfhydryl modified BSA, 0.010 g/L bovine gamma globulin (BgG), and 39 g/L casein (sodium salt), with a pH of 8.0.)

10 6. The particles are separated by application of a magnetic field and washed with 1 M NaCl, separated magnetically and washed with protein buffer. (The protein buffer consists of 0.220 g/L sodium phosphate (monobasic), 4.03 g/L sodium phosphate (dibasic), 8.75 g/L sodium chloride, 1 g/L sulfhydryl modified BSA, and 0.010 g/L BgG, with a pH of 8.0.) The resulting particles are resuspended in solid phase buffer (10 mM sodium barbital, 8.75 g/L sodium chloride, 0.095 % sodium azide, 0.372 g/L disodium EDTA, 2.5 g/L gelatin, 1.0 g/L BgG, 3.0 g/L sulfhydryl modified BSA, 0.02 g/L mouse immunoglobulin G (IgG), 0.02 g/L caprine IgG, 0.2 mL/L amphotericin B, 0.48 mL/L gentamicin sulfate, 0.2 % sodium cholate, and 0.05 g/L antifoam B, adjusted to pH 8.5).

- 15 -

Variations which are consistent with this invention will be apparent to those with skill in the art.

- 16 -

CLAIMS

We claim:

- 5 1. A process for using solid phases coated with casein in binding assays, said solid phases being combined directly or indirectly to an active ingredient used in said binding assay.
- 10 2. The process of claim 1 in which said solid phase is a paramagnetic particle and said binding assay is an immunoassay or a gene probe assay.
- 15 3. The process of claim 1 in which said active ingredient is selected from the group consisting of antigens, antibodies, nucleic acids, nucleic acid polymers, and other receptors.
- 20 4. The process of claim 1 in which said casein is in the form of sodium caseinate or potassium caseinate.
- 25 5. A process for making casein-coated paramagnetic particles containing active ingredients used in binding assays, said process comprising mixing casein with paramagnetic particles and active ingredients, said mixing taking place at 30-60° C. for 5-180 hours to form casein-coated paramagnetic particles, said particles optionally containing one or more components which act as an intermediary reactive entity to assist in the addition of an active ingredient needed in said binding assay.
- 30

- 17 -

6. The process of claim 5 in which said paramagnetic particles had previously been coupled with said active ingredients.

5 7. The process of claim 5 wherein said components are selected from the group consisting of biotin, avidin, and streptavidin.

10 8. The process of claim 5 in which said active ingredients are selected from the group consisting of antigens, antibodies, nucleic acids and nucleic acid polymers.

15 9. process of claim 5 in which said casein is in the form of sodium caseinate or potassium caseinate.

10. The process of claim 5 in which said mixing takes place at 37-50° C. for 14-144 hours.

20 11. Paramagnetic particles coated with casein for use in binding assays, said coated particles comprising 0.05-4.0 grams of casein per gram of paramagnetic particle.

25 12. The paramagnetic particles of claim 11 comprising 0.15-3.2 grams of casein per gram of paramagnetic particles.

30 13. The paramagnetic particles of claim 11 comprising 0.78-1.2 grams of casein per gram of paramagnetic particles.

- 18 -

14. The paramagnetic particle of claim 11 in which said casein is in the form of sodium caseinate or potassium caseinate.
- 5 15. The process of claim 2 in which said binding assay is for an analyte selected from the group consisting of ferritin; T-uptake; thyroxine; 3, 3', 5-triiodothyronine; free 3, 3', 5-triiodothyronine; total human chorionic gonadotropin; CA 19-9; and testosterone.
- 10 16. The process of claim 2 in which interference caused by non-specific binding is reduced.
- 15 17. The process of claim 2 in which interference caused by sample discordance is reduced.
18. The process of claim 2 in which stability is improved due to the addition of casein.
- 20 19. The process of claim 2 in which said paramagnetic particle is also coated with bovine serum albumin.

1/11

Chiron Lig	Control Solid Phase			Modified Solid Phase		
	0.08 g BSA / g PMP			1 g Casein + 0.08 g BSA / g PMP		
	RLU		% Recovery	RLU		% Recovery
Control	Day 0	Day 14	wrt Day 0	Day 0	Day 14	wrt Day 0
9761063	13331	9855	73.9	10315	9430	91.4
9762063	43134	33654	78.0	34951	31779	90.9
9763063	417489	302001	72.3	349680	285432	81.6
9761071	14300	10047	70.3	10867	9790	90.1
9762071	28003	20857	74.5	22336	19673	88.1
9763071	352662	270656	76.7	316818	255631	80.7
Mean			74.3			87.1

Table 1

ACS: 180 ThCG Solid Phases - 37° C Stability

2/11

Chiron Ligand Controls		Day 0			
		Present		Modified	
		RLU	TU Ratio	RLU	TU Ratio
9761071	0.77 - 1.19	217213	1.04	136931	1.06
9762071	0.99 - 1.51	176143	1.28	108564	1.33
9763071	1.30 - 1.98	132623	1.70	80358	1.80

Control	Day 3							Day 7						
	Present				Modified			Present				Modified		
	RLU	ITU Ratio	% Rec		RLU	ITU Ratio	% Rec	RLU	ITU Ratio	% Rec		RLU	ITU Ratio	% Rec
9761071	196681	1.15	110.3		134373	1.07	101.2	190801	1.18	113.9		135095	1.07	101.1
9762071	151770	1.48	115.9		107260	1.34	101.0	151572	1.49	116.0		107824	1.34	101.1
9763071	113409	1.99	116.9		80287	1.80	100.0	114639	1.96	115.6		78584	1.84	102.4

Control	Day 10							Day 14						
	Present				Modified			Present				Modified		
	RLU	ITU Ratio	% Rec		RLU	ITU Ratio	% Rec	RLU	ITU Ratio	% Rec		RLU	ITU Ratio	% Rec
9761071	172986	1.30	125.4		129944	1.11	104.8	166385	1.35	129.8		122499	1.18	111.3
9762071	138110	1.63	127.5		101831	1.42	106.8	131601	1.71	133.6		97931	1.48	111.3
9763071	103776	2.17	127.9		74889	1.93	107.3	99970	2.25	132.4		72412	2.00	111.1

Control	Day 22							Day 28						
	Present				Modified			Present				Modified		
	RLU	ITU Ratio	% Rec		RLU	ITU Ratio	% Rec	RLU	ITU Ratio	% Rec		RLU	ITU Ratio	% Rec
9761071	169901	1.33	127.9		123569	1.17	110.4	167356	1.33	127.9		119414	1.21	114.2
9762071	136337	1.65	128.9		97964	1.47	110.5	139312	1.62	126.6		95585	1.51	113.5
9763071	104469	2.16	127.1		72755	1.99	110.6	103832	2.17	127.6		71668	2.02	112.2

Table 2

ADVIA Centaur TUp Simulated On-Board Stability Study



3/11

		Present	Modified
Precision, (n = 10)		CV%	
TU Ratio	0.98	2.41	1.09
	0.125	1.98	2.74
	0.164	0.82	2.08
Control Recoveries		TU Ratio	
Chiron Ligands	TU Ratio		
9761071	0.77 - 1.19	1.02	1.02
9762071	0.99 - 1.51	1.28	1.31
9763071	1.30 - 1.98	1.66	1.74

Table 3

ACS:180 TUp Performance Data

4/11

**Table 4**

ACS: 180 T4 Performance Data

Specification	Present	Modified
Least Detectable Dose, 0.5 ug/dl	0.24	0.18
% Bo/TC: ≥ 18	24.8	20.6
ED50: 3.79 - 4.83 ug/dl	4.82	4.17
Cal High / Cal Low: 0.10 - 0.55	0.290	0.256
S2 RLU / S6 RLU: 7.71 - 10.3	7.70	9.55
Total Counts, RLU	3282492	3282492
Precision, (n = 10)	CV%	
ug/dl		
1.12	26.5	9.33
4.73	3.85	3.10
10.1	1.66	1.58
19.0	2.26	4.98
Control Recoveries	T4, ug/dl	
Lot		
9761063	4.84	4.91
9762063	9.22	9.00
9763063	15.4	15.6
9761071	3.48	3.92
9762071	6.99	6.95
9763071	14.1	14.5
Mastercurve, ug/dl	RLU	
0	813787	676287
1.12	675847	560528
5.01	391975	291768
10.06	217109	149196
15.1	144808	99469
25.3	87740	58685
36.7	59543	38585
Present	0.1 g BSA/ g PMP	
Modified	0.1 g BSA/ g PMP	
	1.0 g Casein/ g PMP	

5/11

Level	U/mL	Day	With Casein **		Without Casein	
			RLU	RLU % Rec.	RLU	RLU % Rec.
1	22.0	0	15544	100.0	23601	100.0
		4	16400	105.5	12340	52.3
		7	16043	103.2	12329	52.2
		11	15568	100.2	12680	53.7
		14	15174	97.6	12837	54.4
		Mean*		101.6		53.2

Level	U/mL	Day	With Casein **		Without Casein	
			RLU	RLU % Rec.	RLU	RLU % Rec.
2	88.9	0	45080	100.0	52938	100.0
		4	43273	96.0	38291	72.3
		7	44524	98.8	37094	70.1
		11	40778	90.5	38439	72.6
		14	42190	93.6	36420	68.8
		Mean*		94.7		71.0

Level	U/mL	Day	With Casein **		Without Casein	
			RLU	RLU % Rec.	RLU	RLU % Rec.
3	173	0	86516	100.0	98803	100.0
		4	80469	93.0	76285	77.2
		7	81352	94.0	73698	74.6
		11	75595	87.4	72128	73.0
		14	76487	88.4	70349	71.2
		Mean*		90.7		74.0

* Mean % Recovery of Days 4-14

** 1.0 g Casein/g PMP

Table 5

ADVIA Centaur CA 19-9
37° C Solid Phase Stability

6/11




FIG. 1b









FIG. 1a




7/11

**FIG. 2a****FIG. 2b**


8/11

**FIG. 3a****FIG. 3b****FIG. 3c**




9/11



10/11

**FIG. 5**

11/11

**FIG. 6a****FIG. 6b****FIG. 6c**

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/01749

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/543

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 369 361 A (BECTON DICKINSON AND COMPANY) 23 May 1990 (1990-05-23) claims 1,2,4	1-4
A		5-19

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *A* document member of the same patent family

Date of the actual completion of the international search

25 May 2000

Date of mailing of the international search report

07/06/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Bohemen, C

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/01749

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 369361 A	23-05-1990	AT 127589 T	15-09-1995
		AU 625297 B	09-07-1992
		AU 4298789 A	24-05-1990
		CA 2000685 A	17-05-1990
		DE 68924129 D	12-10-1995
		DE 68924129 T	01-02-1996
		DK 575989 A	18-05-1990
		EP 0633472 A	11-01-1995
		ES 2076948 T	16-11-1995
		FI 96802 B	15-05-1996
		GR 3018020 T	29-02-1996
		IE 69041 B	07-08-1996
		JP 2187662 A	23-07-1990
		JP 2589830 B	12-03-1997
		US 5208143 A	04-05-1993

THIS PAGE BLANK (USFIC)